MX347883B - Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos. - Google Patents

Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.

Info

Publication number
MX347883B
MX347883B MX2013004010A MX2013004010A MX347883B MX 347883 B MX347883 B MX 347883B MX 2013004010 A MX2013004010 A MX 2013004010A MX 2013004010 A MX2013004010 A MX 2013004010A MX 347883 B MX347883 B MX 347883B
Authority
MX
Mexico
Prior art keywords
methods
monoclonal
tumor
monoclonal antibody
associated antigen
Prior art date
Application number
MX2013004010A
Other languages
English (en)
Inventor
Anne Elizabeth Wennerberg
Diane A Semer
Original Assignee
East Carolina Univ *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina Univ * filed Critical East Carolina Univ *
Publication of MX347883B publication Critical patent/MX347883B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal seleccionado del grupo que consiste de anticuerpo DS6 monoclonal, anticuerpos monoclonales que específicamente se unen al enlace de epítope o de antígeno a través de anticuerpo DS6 monoclonal, y fragmentos de lo anterior que específicamente se unen al enlace de antígeno epítope, a través de anticuerpo DS6 monoclonal; los métodos de uso de tales anticuerpos y el antígeno aislado, unido a través de los anticuerpos, también se describen.
MX2013004010A 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos. MX347883B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/641,499 US6596503B1 (en) 2000-08-18 2000-08-18 Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
PCT/US2001/041765 WO2002016401A2 (en) 2000-08-18 2001-08-17 Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX347883B true MX347883B (es) 2017-05-16

Family

ID=24572648

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA03001460A MXPA03001460A (es) 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
MX2013004010A MX347883B (es) 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA03001460A MXPA03001460A (es) 2000-08-18 2001-08-17 Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.

Country Status (7)

Country Link
US (5) US6596503B1 (es)
EP (1) EP1362060A4 (es)
AU (1) AU2001289145A1 (es)
CA (1) CA2419270C (es)
GB (1) GB2383331B (es)
MX (2) MXPA03001460A (es)
WO (1) WO2002016401A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2012201260B2 (en) * 2003-07-21 2014-10-23 Immunogen, Inc. A CA6 antigen-specific cytotoxic conjugate and methods of using the same
ATE496944T1 (de) * 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
US7834155B2 (en) * 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
JP2007529201A (ja) * 2004-03-11 2007-10-25 シャーンタ ウェスト インコーポレーティッド Ｒｍ１抗原の治療目的使用方法
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
CA2615761A1 (en) * 2005-08-22 2007-03-01 Immunogen, Inc. Humanized anti-ca6 antibodies and methods of using the same
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
US20070248539A1 (en) * 2006-04-24 2007-10-25 Shantha West Inc. AgRM2 antigen
EP2101813B1 (en) 2006-11-27 2014-04-02 Patrys Limited Novel glycosylated peptide target in neoplastic cells
WO2009015294A1 (en) * 2007-07-24 2009-01-29 Wisconsin Alumni Research Foundation Biomarkers for human papillomavirus-associated cancers
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
EP2303924B1 (en) 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
CN104198709A (zh) * 2008-09-09 2014-12-10 私募蛋白质体公司 肺癌生物标记及其用途
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
SG186953A1 (en) * 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN103415624B (zh) 2010-08-13 2017-03-01 私募蛋白质体公司 胰腺癌生物标记及其用途
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
NZ621733A (en) * 2011-10-24 2015-05-29 Somalogic Inc Lung cancer biomarkers and uses thereof
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
JP2012161321A (ja) * 2012-03-30 2012-08-30 Immunogen Inc Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9989524B2 (en) * 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5366866A (en) 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
WO1994021294A1 (en) 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
US5871941A (en) 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung

Also Published As

Publication number Publication date
EP1362060A2 (en) 2003-11-19
US7351805B2 (en) 2008-04-01
US7507410B2 (en) 2009-03-24
GB2383331B (en) 2004-09-29
US6596503B1 (en) 2003-07-22
WO2002016401A3 (en) 2002-04-11
US20030215895A1 (en) 2003-11-20
CA2419270C (en) 2013-05-14
US20090155930A1 (en) 2009-06-18
MXPA03001460A (es) 2004-12-13
WO2002016401A2 (en) 2002-02-28
GB0306083D0 (en) 2003-04-23
CA2419270A1 (en) 2002-02-28
GB2383331A (en) 2003-06-25
EP1362060A4 (en) 2004-09-08
US20120045776A1 (en) 2012-02-23
US20070196276A1 (en) 2007-08-23
US8067186B2 (en) 2011-11-29
US8728741B2 (en) 2014-05-20
AU2001289145A1 (en) 2002-03-04

Similar Documents

Publication Publication Date Title
MX347883B (es) Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
FI963033A0 (fi) Tuumorirejektioantigeenin esiasteeseen MAGE-1 sitoutuvia monoklonaalisia vasta-aineita, rekombinantti-MAGE-1 ja MAGE-1-peräisiä immunogeenisia peptidejä
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
ES2184660T1 (es) Anticuerpos humanizados que secuestran peptidos abeta.
MX421450B (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19)
EP2301968A3 (en) Humanized monoclonal antibody HPAM4
MX349009B (es) Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
PE20071055A1 (es) Anticuerpos anti mn
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
WO2003034903A3 (en) Psma antibodies and protein multimers
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
WO2008098917A3 (en) Novel antibodies against igf-ir
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
EA201000053A1 (ru) Новые антитела
DE60128893D1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern